Reference

1. **Friedman, C, Callery, S, Jeanes, A, Piaskowski, P, Scott, L, (2005)** Best Infection Control Practices for Patients with Extended Spectrum Beta Lactamase E*nterobacteriacae, International Infection Control Council.*

2. **Agrawal, P, Ghosh, A, Kumar, S, Basu, B, Kapil, K,(2008).**Prevalence of extended spectrum â lactamases among *E. coli* and *K. pneumonia* isolates in tertiary care hospital, *Indian journal Pathology Microbiology*, vol. 51, pp- 139-42.

3. **Pitout, JDD, Laupland, KB, (2008)** Extended Spectrum â Lactamase producing *Enterobacteriaceae: an emerging public health concern. Lancet infect* Dis, vol. 8, pp.159-66.

4. **Yusha.u, MM, Kumurya, AS, and Suleiman, L, (2010)**Prevalence of Extended spectrum â lactamases among Enterobacteriaceae in Murtala Mohammed specialist hospital, Kano,N, *Journal of Pure and Applied Sciences*, vol.3, no.1, pp.169- 172.

5. **Cantón R, Coque TM (2006)** The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 9: 466-475.

6. **Pitout JD, Laupland KB (2008)** Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8: 159-166.

7. **Ramphal R, Ambrose PG (2006)** Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 42 (Suppl 4): S164- 172.

8. **Nakamura T, Komatsu M, Yamasaki K, Fukuda S, Miyamoto Y, et al. (2012)** Epidemiology of Escherichia coli, Klebsiella Species, and Proteus mirabilis strains producing extended-spectrum beta-

lactamases from clinical samples in the Kinki region of Japan. Am J Cli Pathol 137(4): 620-626.

9. **Paterson DL, Bonomo RA (2005)** Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18: 657-686.

10. **Bradford PA (2001)** Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14: 933-951.

11. **Bonnet R (2004)** Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48: 1-14.

12. **Chong Y, Yakusiji H, Ito Y, Kamimura T (2011)** Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a long-term study Japan. Eur J Clin Microbiol Infection Dis 30: 83-87.

13. **Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, et al. (2009)** Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 63: 72-79.

14. **Bell, JM, Chitsaz, M, Turnidge, JD, Barton, M, Walters, LJ, and Jones, RN, 2007,** Prevalence and Significance of a Negative Extended Spectrum â-Lactamase (ESBL) Confirmation Test Result after a Positive ESBL Screening Test Result for Isolates of *scherichia coli* and *Klebsiella pneumoniae*: Results from the SENTRY Asia-Pacific Surveillance Program, *Journal of Clinical Microbiology*, vol. 45, no. 5, pp-1478.1482.

15. **Lal, P, Kapil, A, Das, BK, and Sood, S, (2007**) Occurence of TEM and SHV gene in extended spectrum beta lactamases (ESBLs) producing *Klebsiella spp*.isolated from a tertiary care hospital, *Indian Journal Medical*, 125, pp. 173-178

16. **Rupp, ME, and Paul, D,(2003)** .Extended Spectrum â-Lactamase (ESBL) .Producing Enterobacteriaceae,. *Drugs* Vol. 63, no. 4, pp. 353-356.

17. **Peirano, G, Pitout, JDD, 2010,** Molecular epidemiology of Escherichia coli producing CTX-M â Lactamases : worldwide emergence of clone ST131 025:H4.*International journal of Antimicrobial Agents,* vol.35, pp. 316-321.

18. **K Prashanth, Sk Singh, R Kanugo, S Sharma, P Shashikala, S Joshi, S Jayachandran.** Correlations between genotyping and antibiograms of clinical isolates of *Pseudomonas aeruginosa* from three different south Indian hospitals. IJMM, 201028(2):130-7.

19. **Jacoby, G.A.** AmpC β lactamases. Clin. Microbiol.2009; Rev. 22:161-182.

20. **Li J, Yang JY, Yan LN**. Clinical distribution and antibiotic resistance of non-fermentative gram-negative bacilli infection after liver transplantation. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):543-6.

21. **Falagas ME, Kopterides P.** Riskfactors for the isolation of muti-drug-resistant *Acinetobacterbaumannii* and *Pseudomonas aeruginosa*. J Hosp Infect. 2006 Sep;64(1):7 -15.

22. **Micek, S.T., A.E.Lloyd, D.J.Ritchie, R.M.Reichley, V.J.Fraser, M.H.Kollef.** *Pseudomonas aeruginosa* bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob.Agents Chemother.2005;49:1306-1311.

23. **Alibert-Franco S, Pradines B,** Mahamoud A. Efflux mechanism, an attractive target tocombat MDRPA and *Plasmodium falciparum*.Curr Med chem.2009 ;16(3) :301-17.

24. **American Thoracic society and Infetious diseases society of America.** Guidelines for the management of adults with hospital-acquired,ventilator-associated and health care associated pneumonia. Am. J. Respir. Crit. Care Med.2005;171:388-416.

25. **Lauretti L, Riccio ML, Mazzariol A.** Cloning and characterization of blaVIM2 a new integron borne metallo-beta-lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. Antimicrob Agents Chemother .1999;43:1584-90.

26. **Jumbe N, Louie A, Leary R** Application of mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112:275-85.

27. **Jung R, Fish DN, Obritsch MD.** Surveillance of multi-drug resistant *Pseudomonas aeruginosa* in an urban tertiary care teaching hospital. J Hosp Infect. 2004 Jun;57(2):105-11.

28. **Cao W, Yao D, Zheng R.**Resistance by hypermutable *Pseudomonas aeruginosa* and beta lactamases production.Zhong Nan Da Xue Xue Bao Yi Xue Ban.2009 Jan;34(1):54-8.

29. **Aggarwal R, Chaudhary U, Bala K**. Detection of extended-spectrum beta-lactamase in *Pseudomonas aeruginosa.* Indian J Pathol Microbiol. 2008 Apr-Jun; 51(2):48-51.

30. **Upadhyay, S., Sen, M.R., and Bhattacharjee,A.** Presence of different β-lactamase classes among clinical isolates of *Pseudomonas aeruginosa* expressing AmpC β-lactamase enzyme. J.Infect.Dev. Ctries.2010;4:239-242.

31. **Poirel L, Naas T, Nicholas D, et al.** Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a *Pseudomonas aeruginosa* clinical isolate in France. Antimicrob Agents Chemother.2000;44:891-97.

32. **Haluk Vahaboglu, Recep Ozturk, Gokhan Aygun.** Widespread detection of PER-1-type Extended spectrum beta-lactamases among nosocomial *Acinetobacter* and *Pseudomonas aeruginosa* isolates in Turkey: a nationwide multicenter study. Antimicrobial agents and Chemotherapy.Oct.1997;p.2265-2269.

33. **Lister PD.** Chromosomally-encoded resistance mechanisms of *Pseudomonas aeruginosa*: Am J Pharmacogenomics. 2002; 2(4):235-43.

34. **Mantengoli, E., and G.M Rossolini.** Tn5393d, a complex Tn5393 derivatives carrying the PER-1 extended-spectrum β-lactamase gene and other resistance determinants. Antimicrob.Agents Chemother.2005;49:3289-3296

35. **Laura Pagani, Elisabetta Mantengoli, Roberta Migliavacca,Elisabetta. N., Simona. P., Melissa. S., Rossana. D.et al.** Multifocal Detection of Multidrug resistant *Pseudomonas* Producing the PER-1 Extended-Spectrum β lactamase. Journal of Clinical Microbiology. 2004; 42 (6):2523-2529.

36. **Freshteh S., Mohammad R. S.,Hanieh N.** Molecular identification of ESBL genes blaGES-1,blaVEB-1, blaCTx-M, blaOXA-1, blaOXA-4, blaOXA-10 and blaPER-1 in *Pseudomonas aeruginosa* strains isolated from burns patients by PCR, RFLP and sequencing techniques.Internal Journal of Biology and Life sciences.2010;6(3):138-141.

37. **Mirsalehian A, Feizabadi M, Nakhjavani F, Jabalameli F, Goli H, Kalantari N.** Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase producing *Pseudomonas aeruginosa* strains isolted from burns patients. Burns.2010;36:70-74.

38. **Poriel L., Brians L., Verlinde A., Ide L., Nordman P.**BEL-1 a novel clavulanis acid inhibted extended-spectrum beta-lactamases, and the clas I integronn in 120 *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother.2005;49:3743-3748.

39. **Nordmann P, Ronco E, Naas T ,et al.** Characterization of a novel beta-lactamase from *Pseudomonas aeruginosa*. Antimicrob Agents Chemother .1993;37:962-9.

40. **Poirel L., Docquier J.D., De Luca F., Verlinde A., Ide L., Rossolini G,M., Nordmann, P.**BEL-2, an extended spectrum ß – Lactamase wth increases activity toward expanded –spectrum cephalosporins in *Pseudomonas aeruginosa*. Antimicrobe. Agents Chemother.2010; 54: 533-535.

41. **Nordmann, P., and Mammeri,H.** Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol.2007; 2:297-307.

42. **Poriel L. Nordmann P.,** Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. Curr.Pharm. Biotechnol.2002;3:117-127.

43. Jawetz, Melnick & Adelberg's, Medical Microbiology, 25th Edition.

44. **Xavier, D.E., Picao, R.C., Girardello, R., Fhlberg, L.C., Gales, A.C.** Efflux pumps expression and its association with porin down-regulation and β-lactamase production among *Pseudomonas aeruginosa* causing bloodstream infections in Brazil. BMC Microbiol.2010;10:217.

45. **CLSI.** *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement.* CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.

46. **Lal, P, Kapil, A, Das, BK, and Sood, S, 2007**, Occurence of TEM and SHV gene in extended spectrum beta lactamases (ESBLs) producing *Klebsiella spp. isolated from a* tertiary care hospital, *Indian Journal Medical, 125, pp. 173-178.*